title: Percutaneous osteoid osteoma treatment with combination of radiofrequency and alcohol ablation.
abstract: OBJECTIVE
  To assess the efficacy of percutaneous osteoid osteoma treatment using a combination of radiofrequency ablation (RFA) and alcohol ablation with regard to technical and long-term clinical success.
  
  
  METHODS
  From December 2001 to November 2004, RFA and subsequent alcohol ablation was performed on 54 patients with osteoid osteoma, diagnosed clinically using radiography, computed tomography (CT) and symptoms. Under general anaesthesia, treatment was performed via percutaneous access under thin section (2mm) spiral CT guidance in all cases with an 11 G radiofrequency-compatible coaxial needle and 2mm coaxial drill system and 1.0 cm active tip 17 G non-cooled radiofrequency needle. RFA was performed at 90 degrees C for a period of 6 min. After needle removal, 0.5-1.0 ml absolute alcohol (99.8% concentration) was injected directly into the nidus using a 20 G needle. Patients were discharged within 24h and followed up clinically (at 1 week, 1 month and every 3 months thereafter).
  
  
  RESULTS
  The technical success rate was 100%. Complications occurred in two patients consisting of local mild cellulitis in entry site and peripheral small zone paresthesia on the anterior part of leg. The follow-up period range was 13-48 months (mean+/-SD, 28.2+/-7.4 months). Prompt pain relief and return to normal activities were observed in 52 of 54 patients. Recurrent pain occurred in two patients after a 1 and 3 months period of being pain free, respectively; a second RFA and alcohol ablation was performed achieving successful results. Primary and secondary clinical success rates were 96.3% (52/54 patients) and 100% (2/2 patients), respectively.
  
  
  CONCLUSIONS
  Percutaneous osteoid osteoma treatment with combination of radiofrequency and alcohol ablation is safe, effective and minimally invasive with high primary and secondary success rates. Persistent or recurrent lesions can be effectively re-treated.
authors.affiliation: Noor Medical Imaging Center, Tehran, Iran. akhlaghpoor@nmri-ir.com
authors.forename: S
authors.initials: S
authors.lastname: Akhlaghpoor
authors.forename: A
authors.initials: A
authors.lastname: Tomasian
authors.forename: A
authors.initials: A
authors.lastname: Arjmand Shabestari
authors.forename: M
authors.initials: M
authors.lastname: Ebrahimi
authors.forename: M R
authors.initials: MR
authors.lastname: Alinaghizadeh
mesh_terms: D000293:Adolescent; D000328:Adult; D001859:Bone Neoplasms / Q000000981:diagnostic imaging / Q000601:surgery / Q000628:therapy*; D017115:Catheter Ablation / Q000379:methods*; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D000431:Ethanol / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008297:Male; D010017:Osteoma, Osteoid / Q000000981:diagnostic imaging / Q000601:surgery / Q000628:therapy*; D015641:Radiography, Interventional / Q000379:methods*; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D000431:Ethanol